Tacere Takes Back Asian Rights to HCV Program as It Waits on Pfizer

Although Pfizer's license to the HCV program in markets outside of Asia remains in effect, major restructuring at the big pharma has raised questions about the future of the arrangement.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.